2 completed, 2 recruiting, 2 terminated, 1 active not recruiting. 8 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 2, Recruiting 2, Terminated 2, Active not recruiting 1, Unknown 1 |
| Phase 2 | 5 | Terminated 2, Active not recruiting 1, Completed 1, Unknown 1 |
Follow Mesotheliomas Pleural: new trials by email Literature Review of Mesotheliomas Pleural trials Research Report on Mesotheliomas Pleural
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM) Pembrolizumab, Indocyanine Green (ICG) Image-Guided Surgery, Cisplatin - Mesotheliomas Pleural | Phase 1 | Recruiting | Abramson Cancer Center at Penn Medicine | 20 | 2023-01-10 | 2025-12-04 |
| Oral AMXT 1501 Dicaprate in Combination With IV DFMO AMXT1501, DFMO - Cancer, Solid Tumor | Phase 1 / Phase 2 | Terminated | Aminex Therapeutics, Inc. | 15 | 2022-11-29 | 2024-12-24 |
| A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer TC-510, Fludarabine, Cyclophosphamide - Mesothelioma, Mesotheliomas Pleural | Phase 1 / Phase 2 | Terminated | TCR2 Therapeutics | 14 | 2022-06-21 | 2026-07-13 |
| Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma RSO-021 - Malignant Pleural Effusion, Malignant Pleural Mesothelioma | Phase 1 / Phase 2 | Completed | RS Oncology LLC | 50 | 2022-03-31 | 2026-07-24 |
| dENdritic Cell Therapy Combined With SURgEry in Mesothelioma Mesopher - Mesotheliomas Pleural | Phase 1 | Recruiting | Erasmus Medical Center | 16 | 2021-11-02 | 2026-09-29 |
| Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer gavo-cel, fludarabine, cyclophosphamide - Mesothelioma, Mesothelioma, Malignant | Phase 1 / Phase 2 | Active not recruiting | TCR2 Therapeutics | 57 | 2019-04-15 | 2025-08-27 |
| A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib - Colorectal Cancer Not MSI-H or MMR-deficient, GIST | Phase 1 / Phase 2 | Unknown | Institut Bergonié | 747 | 2018-05-04 | 2023-03-03 |
| CAR T Cells in Mesothelin Expressing Cancers huCART-meso cells - Lung Adenocarcinoma, Ovarian Cancer | Phase 1 | Completed | University of Pennsylvania | 65 | 2017-04-06 | 2025-04-29 |
Mesothelioma, Malignant (8) · Carcinoma, Non-Small-Cell Lung (4) · Ovarian Neoplasms (4) · Mesothelioma (3) · Cholangiocarcinoma (2) · Colorectal Neoplasms (2) · Stomach Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Adenocarcinoma of Lung (1) · Biliary Tract Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Diffuse Intrinsic Pontine Glioma (1)
Adenoma (8) · Lung Diseases (8) · Lung Neoplasms (8) · Neoplasms by Histologic Type (8) · Neoplasms by Site (8) · Neoplasms, Glandular and Epithelial (8) · Neoplasms, Mesothelial (8) · Pleural Neoplasms (8) · Respiratory Tract Diseases (8) · Respiratory Tract Neoplasms (8) · Thoracic Neoplasms (8) · Neoplasms (7) · Adenocarcinoma (5) · Carcinoma (5) · Endocrine Gland Neoplasms (5)
Cyclophosphamide (2) · fludarabine (2) · Cisplatin (1) · Clinical Trials, Phase II as Topic (1) · Indocyanine Green (1) · Ipilimumab (1) · Nivolumab (1) · Pemetrexed (1) · Surgery, Computer-Assisted (1) · Thiostrepton (1) · pembrolizumab (1) · regorafenib (1)
TCR2 Therapeutics (2) · Abramson Cancer Center at Penn Medicine (1) · Aminex Therapeutics, Inc. (1) · Erasmus Medical Center (1) · Institut Bergonié (1) · RS Oncology LLC (1) · University of Pennsylvania (1)
United States (5) · Australia (1) · Canada (1) · France (1) · Netherlands (1) · United Kingdom (1)
Corey Langer, MD (1) · James Spicer, MD (1) · Janos L Tanyi, MD, PhD (1) · Michael Armstrong, MD (1) · Sue Lee, MD (1)
PMID 34965951, PMID 34998048, PMID 37501016, PMID 40204996, PMID 40579407, PMID 42448681
2016 (1)